menu toggle
COVID-19 : 리소스 센터 (자료 센터)
COVID-19에 대한 World Courier의 운영 업데이트 및 포괄적인 정보를 확인하십시오.

With landmark approval, spotlight on cryogenic logistics intensifies

By Andrea Zobel

The cell and gene therapy (CGT) industry achieved a significant milestone at the end of 2022: the first approval of an allogeneic T-cell therapy in the world.

Following a positive recommendation from Europe’s Committee for Medicinal Products for Human Use (CHMP), the European Commission on Monday 19th December formally approved Atara Biotherapeutics’ Ebvallo (tabelecleucel) for the treatment of Epstein-Barr virus-positive, post-transplant lymphoproliferative disease in patients who have undergone at least one prior therapy.

Read the full article to learn more about what this watershed moment means not just for the CGT industry, but for cryogenic logistics too.

About The Author

Andrea Zobel

Senior Director, Personalized Supply Chain
World Courier
View Bio